FZMD (Fuse Medical) NonCurrent Deferred Revenue: $ Mil (As of Jun. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FZMD Fuse Medical Inc FZMD
12 GF Score
Price $0.03
View Full Analysis

What is Fuse Medical NonCurrent Deferred Revenue?

Fuse Medical FZMD 12 NonCurrent Deferred Revenue is $ Mil as of Jun. 2023. GuruFocus rates FZMD with a GF Score™ of 12/100.

Non-Current Deferred Revenue represents the non-current portion of deferred revenue amount as of the balance sheet date. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months.

Fuse Medical's non-current deferred revenue for the quarter that ended in Jun. 2023 was $ Mil.

Fuse Medical NonCurrent Deferred Revenue Related Terms

Fuse Medical NonCurrent Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Fuse Medical's NonCurrent Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fuse Medical NonCurrent Deferred Revenue Chart

Fuse Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Fuse Medical Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
NonCurrent Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
FZMD
12GF Score
Fuse Medical Inc FZMD
NonCurrent Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Revenue of $ Mil mean?
Fuse Medical (FZMD) has a NonCurrent Deferred Revenue of $ Mil as of Jun. 2023. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Fuse Medical and its competitors.
Is Fuse Medical's NonCurrent Deferred Revenue too high?
Fuse Medical's current NonCurrent Deferred Revenue is $ Mil. Overall, Fuse Medical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Fuse Medical's NonCurrent Deferred Revenue compare to GTHP and SONX?
Fuse Medical's NonCurrent Deferred Revenue of $ Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Revenue for a Medical Devices & Instruments company?
A good NonCurrent Deferred Revenue depends on the Medical Devices & Instruments industry context. However, NonCurrent Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Revenue mean?
A high NonCurrent Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Deferred revenue is a liability related to revenue producing activity for which revenue has not yet been recognized and is not expected be recognized in the next twelve months. View historical data on Fuse Medical and its competitors. Fuse Medical's current NonCurrent Deferred Revenue is $ Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fuse Medical stock overvalued right now?
Fuse Medical (FZMD) has a current NonCurrent Deferred Revenue of $ Mil. The current NonCurrent Deferred Revenue is $ Mil. Fuse Medical's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Revenue calculated?
NonCurrent Deferred Revenue is calculated from a company's financial statements. For Fuse Medical (FZMD), the current NonCurrent Deferred Revenue is $ Mil as of Jun. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Fuse Medical Business Description

Address 4343 Sigma Road, Suite 500, Farmers Branch, TX, USA, 75244
Fuse Medical Inc is a manufacturer, distributor, and wholesaler of medical device implants, offering portfolio of orthopedic implants and biologics including: internal fixation products, upper and lower extremity plating and total joint reconstruction implants, soft tissue fixation and augmentation for sports medicine procedures, spinal implants for trauma, degenerative disc disease and deformity indications, and osteo-biologics, regenerative and connective tissues, which include human allografts, substitute bone materials, tendons, and regenerative tissues. Its portfolio of Orthopedic Implants and Biologics provide products to assist surgeons with positive patient outcomes and cost-effective solutions for its customers including hospitals, medical facilities, and sub-distributors.
12GF Score

Get the complete analysis for FZMD

NonCurrent Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.03
Price